The rate of liver cancer diagnoses in the United States increases with age. As of 2021, those aged 75 to 79 years had the highest rates of liver cancer. Risk factors for liver cancer include smoking, drinking alcohol, being overweight or obese, and having diabetes. Who is most likely to get liver cancer? Liver cancer in the United States is much more common among men than women. In 2021, there were 12.3 new liver cancer diagnoses among men per 100,000 population, compared to just five new diagnoses per 100,000 women. Concerning race and ethnicity, non-Hispanic American Indians and Alaska Natives and Hispanic have the highest rates of new liver cancer diagnoses. The five-year survival rate for liver cancer in the United States is around 22 percent, however, this rate is much higher among non-Hispanic Asian and Pacific Islanders than other races and ethnicities. Non-Hispanic Asian and Pacific Islanders have a 33 percent chance of surviving the next five years after a liver cancer diagnosis. Deaths from liver cancer In 2020, there were an estimated 20,262 deaths in the United States due to liver cancer. However, the death rate for liver cancer has decreased over the past few years. In the period 1999 to 2020, the death rate for liver cancer reached a high of five deaths per 100,000 population in 2015 but dropped to 4.6 deaths per 100,000 population by 2020. It is estimated that in 2024, there will be over 19,000 liver and intrahepatic bile duct cancer deaths among men in the United States and 10,700 such deaths among women.

In 2021, there were over *** thousand registrations of newly diagnosed liver cancer in England. With a total of *** cases in this year, the age group most affected by liver cancer in terms of number of cases was that of 70 to 74 year old men. It should of course be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to liver cancer.

According to the data, the rate of liver cancer diagnoses among men in 2021 was around 12 per 100,000 population, while it was five per 100,000 population among women. This statistic depicts the rate of new U.S. liver cancer diagnoses in 2021, by gender.

Primary liver cancer is a significant global health issue, characterized by high incidence and mortality rates worldwide. Accurate diagnosis and classification of subtypes are essential for selecting appropriate treatment options and enhancing patient outcomes. Contrast-enhanced computed tomography (CECT) has proven highly sensitive and specific in diagnosing liver cancer. Currently, publicly available datasets of liver cancer CECT scans are limited and often do not comprehensively cover liver cancer subtypes or include complete phasing of CT scans. We hypothesize that utilizing full-phase 3D CECT images, including the Plain, Arterial, Venous, and Delayed phases, can improve the diagnostic classification performance for liver cancer. To test this hypothesis, we have collected a large dataset from a single medical institution that includes 278 cases of liver cancer, featuring Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), and Combined Hepatocellular-Cholangiocarcinoma (cHCC-CCA), as well as CECT images from 83 non-liver cancer subjects. For each patient, we annotated the liver and lesion regions. This dataset, rich in liver cancer types and complete in CT phasing, facilitates the development and validation of diagnostic classification models and lesion segmentation models tailored to liver cancer CT imaging.The median age of participants was 59 years 51, 67, with 185 males (67.3% of the liver cancer group) . Each patient had complete 3D contrast-enhanced CT (CECT) data across the Plain, Arterial, Venous, and Delayed phases, stored as NIFTI files. A total of 50,560 slices containing lesions were collected, with a median lesion volume of 75.37 cm³ [26.70, 239.24] . The Python code for loading and processing the data can be found on GitHub (https://github.com/ljwa2323/PLC_CECT).

In the period 2013 to 2017, over ** percent of those aged between 15 and 44 years who were diagnosed with liver cancer in England survived for at least *** year after being diagnosed, while ** percent survived for five years. Over the period provided, the older age groups have a lower survival rate than the younger age groups.

Age-standardized incidence rates and annual percent changes in primary liver cancer rates, 1978–2018.

IntroductionLiver cancer is one of the most common malignant gastrointestinal tumors worldwide. This study intends to provide insight into the epidemiological characteristics and development trends of liver cancer incidence and mortality from 2010 to 2020 in Guangzhou, China.MethodsData were collected from the Cancer Registry and Reporting Office of Guangzhou Center for Disease Control and Prevention. Cross-sectional study, Joinpoint regression (JPR) model, and Age-Period-Cohort (APC) model were conducted to analyze the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) trend of liver cancer among the entire study period.ResultsThe age-standardized incidence and mortality of liver cancer in Guangzhou showed an overall decreasing trend. The disparity in risk of morbidity and mortality between the two sexes for liver cancer is increasing. The cohort effect was the most significant among those born in 1965~1969, and the risk of liver cancer incidence and mortality in the total population increased and then decreased with the birth cohort. Compared with the birth cohort born in 1950~1954 (the reference cohort), the risk of liver cancer incidence and mortality in the males born in 1995~1999 decreased by 32% and 41%, respectively, while the risk in the females decreased by 31% and 32%, respectively.ConclusionsThe early detection, prevention, clinical diagnosis, and treatment of liver cancer in Guangzhou have made remarkable achievements in recent years. However, the risk of liver cancer in the elderly and the middle-aged males is still at a high level. Therefore, the publicity of knowledge related to the prevention and treatment of liver cancer among the relevant population groups should be actively carried out to enhance the rate of early diagnosis and treatment of liver cancer and to advocate a healthier lifestyle.

BackgroundLiver cancer due to hepatitis C (LCDHC) is one of the leading causes of cancer-related deaths worldwide, and the burden of LCDHC is increasing. We aimed to report the burden of LCDHC at the global, regional, and national levels in 204 countries from 1990 to 2019, stratified by etiology, sex, age, and Sociodemographic Index.MethodsData on LCDHC were available from the Global Burden of Disease, Injuries, and Risk Factors (GBD) study 2019. Numbers and age-standardized mortality, incidence, and disability-adjusted life year (DALY) rates per 100,000 population were estimated through a systematic analysis of modeled data from the GBD 2019 study. The trends in the LCDHC burden were assessed using the annual percentage change.ResultsGlobally, in 2019, there were 152,225 new cases, 141,810 deaths, and 2,878,024 DALYs due to LCDHC. From 1990 to 2019, the number of incidences, mortality, and DALY cases increased by 80.68%, 67.50%, and 37.20%, respectively. However, the age-standardized incidence, mortality, and DALY rate had a decreasing trend during this period. In 2019, the highest age-standardized incidence rates (ASIRs) of LCDHC were found in high-income Asia Pacific, North Africa and the Middle East, and Central Asia. At the regional level, Mongolia, Egypt, and Japan had the three highest ASIRs in 2019. The incidence rates of LCDHC were higher in men and increased with age, with a peak incidence in the 95+ age group for women and the 85–89 age group for men in 2019. A nonlinear association was found between the age-standardized rates of LCDHC and sociodemographic index values at the regional and national levels.ConclusionsAlthough the age-standardized rates of LCDHC have decreased, the absolute numbers of incident cases, deaths, and DALYs have increased, indicating that LCDHC remains a significant global burden. In addition, the burden of LCDHC varies geographically. Male and older adult/s individuals have a higher burden of LCDHC. Our findings provide insight into the global burden trend of LCDHC. Policymakers should establish appropriate methods to achieve the HCV elimination target by 2030 and reducing the burden of LCDHC.

In 2021, *** individuals in Scotland were diagnosed with liver cancer. The most affected age group was those aged 70 to 74 years with *** cases, followed by the age group 75 to 79 years with *** cases. This statistic depicts the number of newly diagnosed liver cancer cases in Scotland in 2021, by age

The Liver Cancer Therapeutics Market is Segmented by Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, and More), Therapy (Targeted Therapy, Chemotherapy, and More), Age Group (Adults, Geriatric, and Pediatric), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific and More). The Market and Forecasts are Provided in Terms of Value (USD).

This repository enables external validation of the artificial neural network published in our article with the same title using the pretrained ANN as described in the manuscript.

The parameters included in the model are:

Demographics - Gender = 'MALE' or 'FEMALE' - BCLC = Barcelona Clinic Liver Cancer staging system (values: A, B, C, D) - Age = age at second TACE, in years

Etiology / concomitant disease - Nicotine abuse, Obesity, Diabetes, Etiology alcohol (in case of liver cirrhosis due to alcohol abuse), Etiology HBV (in case of liver cirrhosis due to chronic hepatitis B infection), Etiology HCV (in case of liver cirrhosis due to chronic hepatitis C infection), Etiology NASH (in case of NASH), Etiology unknown (in case of liver cirrhosis of unknown etiology). All these parameters can take values: 0 = false and 1 = true.

Tumor related - Baseline tumor number = number of tumor lesions at baseline - Diffuse tumor = diffuse tumor growth pattern (values: 0 = nodular pattern and 1 = diffuse pattern) - Tumor size 1st, Tumor size 2nd: mRECIST evaluation of cross-sectional imaging prior to first and prior to second TACE - Treatment response: radiological response after first TACE (values: 0 = false and 1 = true)

Laboratory / liver function - Sodium 1st, Sodium 2nd, Bilirubin 1st, Bilirubin 2nd, Albumin 1st, Albumin 2nd, AST 1st, AST 2nd, ALT 1st, ALT 2nd, INR 1st, INR 2nd, Thrombocyte count 1st, Thrombocyte count 2nd, AFP 1st, AFP 2nd: laboratory values prior to first and prior to second TACE - Child Pugh score 1st, Child Pugh score 2nd, MELD score 1st, MELD score 2nd: Child Pugh and MELD score prior to first and prior to second TACE

Sarcopenia - SMI 1st, SMI 2nd: skeletal muscle index/psoas muscle index measured at the level of the L3 vertebrae prior to first and prior to second TACE

Type of TACE: - TACE = 'cTACE' or 'DEB-TACE'

Imaging used for response evaluation prior to second TACE: - Imaging = 'CT' or 'MRI'

This record contains raw data related to article “Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis"

Abstract

Background and aims: Autoimmune hepatitis (AIH) is a rare chronic liver disease of unknown aetiology; the risk of hepatocellular carcinoma (HCC) remains unclear and risk factors are not well-defined. We aimed to investigate the risk of HCC across a multicentre AIH cohort and to identify predictive factors.

Methods: We performed a retrospective, observational, multicentric study of patients included in the International Autoimmune Hepatitis Group Retrospective Registry. The assessed clinical outcomes were HCC development, liver transplantation, and death. Fine and Gray regression analysis stratified by centre was applied to determine the effects of individual covariates; the cumulative incidence of HCC was estimated using the competing risk method with death as a competing risk.

Results: A total of 1,428 patients diagnosed with AIH from 1980 to 2020 from 22 eligible centres across Europe and Canada were included, with a median follow-up of 11.1 years (interquartile range 5.2-15.9). Two hundred and ninety-three (20.5%) patients had cirrhosis at diagnosis. During follow-up, 24 patients developed HCC (1.7%), an incidence rate of 1.44 cases/1,000 patient-years; the cumulative incidence of HCC increased over time (0.6% at 5 years, 0.9% at 10 years, 2.7% at 20 years, and 6.6% at 30 years of follow-up). Patients who developed cirrhosis during follow-up had a significantly higher incidence of HCC. The cumulative incidence of HCC was 2.6%, 4.6%, 5.6% and 6.6% at 5, 10, 15, and 20 years after the development of cirrhosis, respectively. Obesity (hazard ratio [HR] 2.94, p = 0.04), cirrhosis (HR 3.17, p = 0.01), and AIH/PSC variant syndrome (HR 5.18, p = 0.007) at baseline were independent risk factors for HCC development.

Conclusions: HCC incidence in AIH is low even after cirrhosis development and is associated with risk factors including obesity, cirrhosis, and AIH/PSC variant syndrome.

Impact and implications: The risk of developing hepatocellular carcinoma (HCC) in individuals with autoimmune hepatitis (AIH) seems to be lower than for other aetiologies of chronic liver disease. Yet, solid data for this specific patient group remain elusive, given that most of the existing evidence comes from small, single-centre studies. In our study, we found that HCC incidence in patients with AIH is low even after the onset of cirrhosis. Additionally, factors such as advanced age, obesity, cirrhosis, alcohol consumption, and the presence of the AIH/PSC variant syndrome at the time of AIH diagnosis are linked to a higher risk of HCC. Based on these findings, there seems to be merit in adopting a specialized HCC monitoring programme for patients with AIH based on their individual risk factors.

Papumpare district in the west Arunachal region in India had age adjusted incidence rate of liver cancer cases among male of over ** cases per million male adults between the years 2012 and 2016. Whereas, the age incidence rate of liver cancer among women in that region was over ** cases per million females in the country.

For current version see: https://data.sandiegocounty.gov/Health/2021-Non-Communicable-Chronic-Diseases/v7dt-rwpx

Basic Metadata *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

Liver Cancer Therapeutics Market Outlook

The global liver cancer therapeutics market size in 2023 was estimated at USD 6.5 billion, with projections indicating that it will grow to approximately USD 10.8 billion by 2032. This growth corresponds to a compound annual growth rate (CAGR) of 5.8% during the forecast period. This growth is primarily driven by the increasing incidence of liver cancer worldwide, advancements in treatment methodologies, and heightened awareness about early diagnosis and treatment options. The rising prevalence of risk factors such as obesity, alcohol consumption, and hepatitis infections further contributes to the expansion of this market. Additionally, the continuous development of novel therapeutics and increased investments in research and development are expected to further fuel market growth.

One of the primary growth drivers of the liver cancer therapeutics market is the increasing global incidence of liver cancer. Factors such as lifestyle changes, increased alcohol consumption, and the growing prevalence of conditions like hepatitis B and C and non-alcoholic fatty liver disease are contributing to the rising cases of liver cancer. The aging population also plays a significant role, as the risk of developing liver cancer increases with age. Furthermore, governments and non-profit organizations around the world are implementing initiatives to raise awareness about liver cancer prevention and early detection, which is expected to lead to higher diagnosis rates and subsequent treatment adoption.

Advancements in medical technology and treatment methodologies significantly contribute to the growth of the liver cancer therapeutics market. Innovations in targeted therapy and immunotherapy have provided new avenues for treating liver cancer, offering more personalized and effective treatment options with fewer side effects compared to traditional therapies. The development of combination therapies, which utilize multiple drugs or treatment types to increase efficacy, is also gaining traction. Furthermore, advancements in diagnostic tools, including imaging techniques and biomarkers, are improving the accuracy of liver cancer diagnosis, enabling earlier and more effective intervention.

Another important factor driving market growth is the increasing investment in research and development by pharmaceutical companies. As the demand for more effective liver cancer treatments grows, companies are investing heavily in the development of new drugs and therapies. This is not only leading to the introduction of novel treatment options but also enhancing the efficacy of existing ones. Collaborations between pharmaceutical companies, research institutions, and healthcare providers are fostering innovation and accelerating the development of new liver cancer therapies. Additionally, regulatory bodies are streamlining approval processes for new drugs, encouraging companies to bring their novel therapeutics to market more rapidly.

Regionally, the liver cancer therapeutics market is experiencing varied growth patterns, with the Asia Pacific region anticipated to witness the highest CAGR. This growth is driven by the high prevalence of liver cancer in countries such as China and India, coupled with increasing healthcare expenditure and improving healthcare infrastructure. North America holds a significant market share, owing to advanced healthcare systems, high awareness levels, and the presence of major pharmaceutical companies. Europe is also a key market, supported by government initiatives and a growing focus on research and development in cancer treatment. Meanwhile, Latin America and the Middle East & Africa regions are expected to see moderate growth, driven by improving healthcare access and increasing awareness about liver cancer.

Treatment Type Analysis

The liver cancer therapeutics market, when segmented by treatment type, encompasses targeted therapy, immunotherapy, chemotherapy, radiation therapy, and other emerging treatments. Targeted therapy has emerged as a cornerstone in liver cancer treatment, as it allows for the direct targeting of cancer cells with minimal impact on surrounding healthy tissues. This approach is increasingly favored due to its efficacy and reduced side effect profile compared to traditional chemotherapy. The development of new targeted drugs continues to expand this segment, driven by ongoing research into the molecular and genetic underpinnings of liver cancer that allow for more precise targeting of cancer cells.

Immunotherapy represents a rapidly growing segment in the liver cancer therapeutics market. This inno

BackgroundLow-fat diet reduces the risk of chronic metabolic diseases such as obesity and diabetes, which exhibit overlapping mechanisms with liver cancer. However, the association between low-fat diet and liver cancer risk remains unclear.AimTo investigate whether adherence to low-fat diet is associated with a reduced risk of liver cancer in a prospective study.Materials and methodsData of participants in this study were collected from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. A low-fat diet score was calculated to reflect adherence to low-fat dietary pattern, with higher scores indicating greater adherence. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for liver cancer incidence with adjustment for potential covariates. Restricted cubic spline model was used to characterize liver cancer risk across the full range of the low-fat diet score. Prespecified subgroup analyses were used to identify potential impact modifiers. Sensitivity analyses were performed to test the robustness of this association.ResultsA total of 98,455 participants were included in the present analysis. The mean (standard deviation) age, low-fat diet score, and follow-up time were 65.52 (5.73) years, 14.99 (6.27) points, and 8.86 (1.90) years, respectively. During 872639.5 person-years of follow-up, 91 liver cancers occurred, with an overall incidence rate of 0.01 cases per 100 person-years. In the fully adjusted Cox model, the highest versus the lowest quartile of low-fat diet score was found to be associated with a reduced risk of liver cancer (HRQ4 vs. Q1: 0.458; 95% CI: 0.218, 0.964; P = 0.035 for trend), which remained associated through a series of sensitivity analyses. The restricted cubic spline model showed a linear dose–response association between low-fat diet score and liver cancer incidence (p = 0.482 for non-linear). Subgroup analyses did not show significant interaction between low-fat diet score and potential impact modifiers in the incidence of liver cancer.ConclusionIn this study, low-fat diet score is associated with reduced liver cancer risk in the US population, indicating that adherence to low-fat diet may be helpful for liver cancer prevention. Future studies should validate our findings in other populations.

Introduction: Disparities in the incidence, mortality, and survival of cancer types between urban and rural areas in China reflect the effects of different risk factor exposure, education, and different medical availability. We aimed to characterize the disparities in the incidence, mortality, and survivals of cancer types between urban and rural areas in Shanghai, China, 2002-2015.Materials and Methods: The incidence and mortality were standardized by Segi's world standard population. Trends in the incidence and mortality of cancers were compared using annual percent change. The 5-year observed and relative survivals were calculated with life table and Ederer II methods.Results: Age-standardized incidences and mortalities were 212.55/105 and 109.45/105 in urban areas and 210.14/105 and 103.99/105 in rural areas, respectively. Female breast cancer and colorectal cancer occurred more frequently in urban than in rural areas, quite in contrast to liver cancer and cervical cancer. Cancers of lung and bronchus, liver, stomach, and colon and rectum were the leading causes of cancer death in both areas. Age-standardized incidence of female breast cancer and colorectal cancer in urban areas increased while gastric cancer and liver cancer decreased in both areas. Age-standardized mortalities of cancers of breast, esophagus, stomach, colon and rectum, liver, and lung and bronchus decreased in both areas. For all cancers combined, the 5-year observed and relative survivals of cancer patients were higher in urban than in rural areas. The 5-year observed and relative survivals of cancers of liver, pancreas, stomach, brain and central nervous system (CNS), and prostate were higher in urban than in rural areas. The 5-year observed and relative survivals of cervical cancer were higher in rural than in urban areas.Conclusions: Factors promoting female breast cancer and colorectal cancer in urban areas and liver cancer and cervical cancer in rural areas should be specifically intervened in cancer prophylaxis. Improved medical services can greatly prolong the survival of major cancers in rural areas.

Introduction: Optimal treatment of hepatocellular carcinoma (HCC) beyond the Milan criteria is in debate. We aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC) –A/B HCC beyond the Milan criteria with survival benefit. Methods: Patients with BCLC-A/B HCC beyond the Milan criteria at the National Taiwan University Hospital during 2005 and 2019 were screened and those who received transarterial chemoembolization (TACE) or SR were consecutively included. The tumor burden was classified by the seven-eleven criteria into low (≤7), intermediate (7-11) or high (>11). Multivariable cox proportional hazard regression analysis was used for outcome prediction. Results: Overall, 474 patients who received SR (n=247), and TACE (n=227) were enrolled. Patients underwent SR were significantly younger with better liver reserve. There were 76 (31%), and 129 (57%) deaths in the SR and TACE groups after a median follow-up of 3.9 and 2.1 years, respectively. The seven-eleven criteria could distinguish median overall survival (OS) among low (n=149), intermediate (n=203), and high (n=122) tumor burden groups (7.7 vs. 6.9 vs. 2.8 years, respectively, P < 0.001). Patients receiving SR had a significantly higher median OS compared with TACE in those with intermediate (8.2 vs. 2.6 years, P < 0.001) and high (5.6 vs. 1.5 years, P = 0.001) tumor burden. After adjustment for age, sex, and liver reserve, SR was predictive for better OS in intermediate (adjusted hazard ratio [aHR]: 0.45, 95% CI: 0.27-0.75) and high tumor burden groups (aHR: 0.54, 95% CI: 0.32-0.92). The survival benefit of SR especially confines to patients within 3 tumors. Conclusions: In patients with BCLC-A/B HCC beyond the Milan criteria with tumor burden beyond the up-to-7 criteria but within 3 tumors, SR has better OS than TACE and should be considered in resectable patients.

ObjectiveLiver cancer is one of the most common causes of cancer-related death. Understanding how demographic factors influence mortality due to liver cancer is crucial for optimizing disease-control strategies. We aimed to characterize the long-term trends in the mortality and years of life lost (YLL) of liver cancer in Shanghai, China, 1973–2019, and quantitatively analyze the contributions of demographic and non-demographic factors on the mortality of liver cancer.MethodsUsing mortality data from the Mortality Registration System of Pudong New Area, the largest district of Shanghai with a population of permanent resident of 5.68 million, during 1973–2019, we analyzed the temporal trends for the mortality rates and YLL by Joinpoint Regression Program. The difference decomposition method was employed to estimate the increasing mortality rates related to demographic and non-demographic factors.ResultsA total of 21,530 deaths from liver cancer occurred from 1973 to 2019. The crude mortality rates (CMR) and age-standardized mortality rate by Segi's world standard population (ASMRW) of liver cancer were 26.73/105 person-years and 15.72/105 person-years, respectively. The CMR, ASMRW, and YLL rates of liver cancer showed significantly decreasing trends in males, females and the total population from 1973 to 2019, whereas the upward trends in the YLL were seen in males, females and the total population (all P < 0.05). A significant upward trend was observed in the increased CMR caused by demographic factors, but the changing rate caused by non-demographic factors decreased.ConclusionsThe CMR and ASMRW of liver cancer continually decreased although YLL increased during 1973–2019 in Pudong New Area, Shanghai. The demographic factors, especially aging, might be responsible for the increase in the mortality of liver cancer. More effective prevention strategies tailored to liver cancer are needed to further reduce its disease burden in the elderly population.

The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) data collection is part of a larger effort to build a research community focused on connecting cancer phenotypes to genotypes by providing clinical images matched to subjects from The Cancer Genome Atlas (TCGA). Clinical, genetic, and pathological data resides in the Genomic Data Commons (GDC) Data Portal while the radiological data is stored on The Cancer Imaging Archive (TCIA).

Matched TCGA patient identifiers allow researchers to explore the TCGA/TCIA databases for correlations between tissue genotype, radiological phenotype and patient outcomes. Tissues for TCGA were collected from many sites all over the world in order to reach their accrual targets, usually around 500 specimens per cancer type. For this reason the image data sets are also extremely heterogeneous in terms of scanner modalities, manufacturers and acquisition protocols. In most cases the images were acquired as part of routine care and not as part of a controlled research study or clinical trial.

CIP TCGA Radiology Initiative

Imaging Source Site (ISS) Groups are being populated and governed by participants from institutions that have provided imaging data to the archive for a given cancer type. Modeled after TCGA analysis groups, ISS groups are given the opportunity to publish a marker paper for a given cancer type per the guidelines in the table above. This opportunity will generate increased participation in building these multi-institutional data sets as they become an open community resource. Learn more about the CIP TCGA Radiology Initiative.